JP2021510545A5 - - Google Patents

Download PDF

Info

Publication number
JP2021510545A5
JP2021510545A5 JP2020559043A JP2020559043A JP2021510545A5 JP 2021510545 A5 JP2021510545 A5 JP 2021510545A5 JP 2020559043 A JP2020559043 A JP 2020559043A JP 2020559043 A JP2020559043 A JP 2020559043A JP 2021510545 A5 JP2021510545 A5 JP 2021510545A5
Authority
JP
Japan
Prior art keywords
immune cell
antigen
immune
vector
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020559043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021510545A (ja
JP7068498B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/050194 external-priority patent/WO2019138354A1/en
Publication of JP2021510545A publication Critical patent/JP2021510545A/ja
Publication of JP2021510545A5 publication Critical patent/JP2021510545A5/ja
Priority to JP2022074779A priority Critical patent/JP7394914B2/ja
Application granted granted Critical
Publication of JP7068498B2 publication Critical patent/JP7068498B2/ja
Priority to JP2023200890A priority patent/JP7763824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559043A 2018-01-12 2019-01-10 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物 Active JP7068498B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022074779A JP7394914B2 (ja) 2018-01-12 2022-04-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
JP2023200890A JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20180004238 2018-01-12
KR10-2018-0004238 2018-01-12
PCT/IB2019/050194 WO2019138354A1 (en) 2018-01-12 2019-01-10 Enhanced immune cells using dual shrna and composition including the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022074779A Division JP7394914B2 (ja) 2018-01-12 2022-04-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2021510545A JP2021510545A (ja) 2021-04-30
JP2021510545A5 true JP2021510545A5 (https=) 2021-12-23
JP7068498B2 JP7068498B2 (ja) 2022-05-16

Family

ID=67218229

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020559043A Active JP7068498B2 (ja) 2018-01-12 2019-01-10 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
JP2022074779A Active JP7394914B2 (ja) 2018-01-12 2022-04-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
JP2023200890A Active JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022074779A Active JP7394914B2 (ja) 2018-01-12 2022-04-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
JP2023200890A Active JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Country Status (14)

Country Link
US (4) US11679129B2 (https=)
EP (2) EP4006153B1 (https=)
JP (3) JP7068498B2 (https=)
KR (2) KR102327512B1 (https=)
CN (1) CN111801421B (https=)
AU (2) AU2019206425B2 (https=)
CA (1) CA3088234A1 (https=)
DK (1) DK3737765T4 (https=)
ES (2) ES2990966T3 (https=)
FI (1) FI3737765T4 (https=)
PL (1) PL3737765T5 (https=)
PT (1) PT3737765T (https=)
SG (1) SG11202006606YA (https=)
WO (1) WO2019138354A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3697435A1 (en) * 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
PT3737765T (pt) 2018-01-12 2022-03-11 Curocell Inc Células imunitárias melhoradas utilizando shrna duplo e composição incluindo as mesmas
CN109485732B (zh) * 2018-12-20 2021-09-24 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
JP7633180B2 (ja) * 2019-05-02 2025-02-19 セリアド オンコロジー エス.アー. マルチプレックス化干渉rnaを有する細胞
KR20220081972A (ko) * 2019-07-17 2022-06-16 주식회사 큐로셀 이중 shrna를 이용하는 향상된 면역 세포 및 이를 포함하는 조성물
BR112022001331A2 (pt) 2019-07-26 2022-06-14 Janssen Biotech Inc Receptor quimérico de antígeno (car) anti-hk2
CN120905142A (zh) * 2019-11-20 2025-11-07 卡瑟里克斯私人有限公司 用于提供具有增强功能的免疫细胞的方法
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
WO2022011065A1 (en) * 2020-07-07 2022-01-13 The Nemours Foundation Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer
CN114075562A (zh) * 2021-03-10 2022-02-22 北京肿瘤医院(北京大学肿瘤医院) Mage-c3抑制剂及其作为制备治疗和/或预防食管鳞状细胞癌药物的用途
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用
CN113403208A (zh) * 2021-06-15 2021-09-17 江西科技师范大学 高效鉴定米曲霉CRISPR/Cas9突变体的方法
AU2022299474A1 (en) * 2021-06-23 2023-12-21 Versameb Ag Compositions and methods for modulating expression of genes
AU2022366987A1 (en) 2021-10-14 2024-05-16 Arsenal Biosciences, Inc. Immune cells having co-expressed shrnas and logic gate systems
WO2023147776A1 (en) * 2022-02-07 2023-08-10 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
EP4282963A1 (en) 2022-05-23 2023-11-29 Eberhard Karls Universität Tübingen, Medizinische Fakultät Nucleic acid modified biological cell with expansion-dependent gene expression
CN114836428B (zh) * 2022-06-08 2024-03-26 华东师范大学 一种tigit基因干扰的嵌合抗原受体nk细胞及其应用
WO2023238103A1 (en) * 2022-06-10 2023-12-14 Curocell Inc. Car-t therapy for treating cancer
CN116983322B (zh) * 2022-09-15 2026-04-07 圣诺生物医药技术(苏州)有限公司 用于治疗肺癌、胰腺癌、肝癌和结直肠癌的小核酸干扰药物
KR20250158048A (ko) 2023-03-03 2025-11-05 아스널 바이오사이언시스, 인크. Psma 및 ca9을 표적으로 하는 시스템
WO2024218204A1 (en) * 2023-04-18 2024-10-24 Uniqure Biopharma B.V. Gene delivery vehicles comprising rna and antibodies
CN116515836B (zh) * 2023-05-09 2023-12-01 中国人民解放军军事科学院军事医学研究院 抑制MerTK表达的shRNA、腺相关病毒及其应用
CN117587014B (zh) * 2023-11-24 2025-01-24 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
CA2406864A1 (en) 2000-02-24 2001-08-30 Life Technologies Corporation Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
US20080293142A1 (en) * 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Construction
EP2152874A2 (en) 2007-04-26 2010-02-17 University of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
ES2739804T3 (es) 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
EP3549611B1 (en) 2011-07-29 2021-06-30 The Trustees of the University of Pennsylvania Switch costimulatory receptors
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
DK2958943T3 (da) 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
ES2897579T3 (es) 2013-06-10 2022-03-01 Dana Farber Cancer Inst Inc Métodos y composiciones para reducir la inmunosupresión por células tumorales
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
JP6663859B2 (ja) 2014-05-20 2020-03-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション ハンチントン病の治療化合物
WO2016069282A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
ES2592578B1 (es) 2015-05-07 2017-12-18 Dode, S.A. Mejoras introducidas en la patente de invención "Procedimiento para el tratamiento de granos de maíz destinados a la obtención de palomitas de maíz por medio de aparatos microondas y producto obtenido"
WO2017040945A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
US10711282B2 (en) * 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
JP6908528B2 (ja) 2015-12-11 2021-07-28 ローム株式会社 半導体装置
CN106967681B (zh) * 2016-01-13 2020-06-05 北京马力喏生物科技有限公司 治疗脑胶质母细胞瘤的治疗组合物
CN106967685B (zh) 2016-01-13 2020-06-02 北京马力喏生物科技有限公司 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2018012895A1 (ko) * 2016-07-14 2018-01-18 주식회사 큐로셀 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
EP3512950A1 (en) * 2016-09-14 2019-07-24 Benitec Biopharma Limited REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF
US12447213B2 (en) * 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
CN107058390A (zh) * 2017-01-17 2017-08-18 上海交通大学医学院附属第九人民医院 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
EP3585398A4 (en) * 2017-02-23 2020-08-19 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
PT3737765T (pt) 2018-01-12 2022-03-11 Curocell Inc Células imunitárias melhoradas utilizando shrna duplo e composição incluindo as mesmas
CN110904045A (zh) 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
KR20220081972A (ko) 2019-07-17 2022-06-16 주식회사 큐로셀 이중 shrna를 이용하는 향상된 면역 세포 및 이를 포함하는 조성물

Similar Documents

Publication Publication Date Title
JP2021510545A5 (https=)
JP7394914B2 (ja) 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
US12295968B2 (en) Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20260102489A1 (en) Combination of vaccination and inhibition of the pd-1 pathway
HRP20191033T1 (hr) Nukleinska kiselina koja sadrži ili kodira za histon peteljka-omča i poli(a) sekvencu ili poliadenilacijski signal za povećanje ekspresije kodiranog tumorskog antigena
Capece et al. Targeting costimulatory molecules to improve antitumor immunity
RU2008135318A (ru) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии неопластических или инфекционных заболеваний
HRP20140763T1 (hr) Pripravak koji sadrži kompleksiranu(m)rnk i golu mrnk za pružanje ili poboljšanje imunostimulacijskog odgovora kod sisavca i njihova uporaba
US20220348928A1 (en) Enhanced immune cells using dual shrna and composition including the same